All Stories

  1. Antifungal Drugs Discovered Through Synthetic Chemistry and Introduced for Human Use from 1895 to September 2026
  2. Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026
  3. Natural product inspired antibiotics approved for human use – 1943 to 2025
  4. Rapid profiling of polymyxin B susceptibility in gram-negative bacteria with a novel polymyxin-derived fluorescent probe
  5. The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives
  6. Extracting Value from Marine and Microbial Natural Product Artifacts and Chemical Reactivity
  7. Natural product-derived compounds in clinical trials and drug approvals
  8. A Review of Antibacterial Candidates with New Modes of Action
  9. Correction: Antibiotics in the clinical pipeline as of December 2022
  10. Turonicin A, an Antifungal Linear Polyene Polyketide from an Australian Streptomyces sp.
  11. Nanoscaled Discovery of a Shunt Rifamycin from Salinispora arenicola Using a Three-Color GFP-Tagged Staphylococcus aureus Macrophage Infection Assay
  12. Antibiotics in the clinical pipeline as of December 2022
  13. Natural products as anthelmintics: safeguarding animal health
  14. Nanoscaled discovery of a shunt rifamycin fromSalinispora arenicolausing a three-colour GFP-taggedStaphylococcus aureusmacrophage infection assay
  15. A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections
  16. Isolation and Characterization of Werneria Chromene and Dihydroxyacidissimol from Burkillanthus malaccensis (Ridl.) Swingle
  17. Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!”
  18. Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed
  19. Discovery of brevijanazines from Aspergillus brevijanus reveals the molecular basis for p-nitrobenzoic acid in fungi
  20. Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae Is Predominately Driven by Chloramphenicol
  21. Antibiotics in the clinical pipeline in October 2019
  22. Trivirensols: Selectively Bacteriostatic Sesquiterpene Trimers from the Australian Termite Nest-Derived Fungus Trichoderma virens CMB-TN16
  23. Structure-Function Studies of Polymyxin B Lipononapeptides
  24. Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity
  25. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
  26. Octapeptin C4 Induces Less Resistance and Novel Mutations in an Epidemic Carbapenemase-producing Klebsiella pneumoniae ST258 Clinical Isolate Compared to Polymyxins
  27. 5,6,7,3′,4′,5′-Hexamethoxyflavone from the Australian plant Eremophila debilis (Myoporaceae)
  28. Synthesis of deuterium-labelled analogues of NLRP3 inflammasome inhibitor MCC950
  29. Developments in Glycopeptide Antibiotics
  30. Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria
  31. Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria
  32. Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia
  33. Old dogs and new tricks in antimicrobial discovery
  34. Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950
  35. Disruption of de Novo Adenosine Triphosphate (ATP) Biosynthesis Abolishes Virulence inCryptococcus neoformans
  36. Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis
  37. Fluorescent Trimethoprim Conjugate Probes To Assess Drug Accumulation in Wild Type and MutantEscherichia coli
  38. Antibiotics in the clinical pipeline at the end of 2015
  39. A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance
  40. Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
  41. Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum
  42. Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
  43. Mucin Binding Reduces Colistin Antimicrobial Activity
  44. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics—polymyxin B and chloramphenicol
  45. Evaluation of biomarkers for in vitro prediction of drug‐induced nephrotoxicity: comparison of HK ‐2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells
  46. Gargantulide A, a Complex 52-Membered Macrolactone Showing Antibacterial Activity from Streptomyces sp.
  47. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
  48. Synthesis of norbornane bisether antibiotics via silver-mediated alkylation
  49. Synthesis and evaluation of cationic norbornanes as peptidomimetic antibacterial agents
  50. Ramoplanin at Bactericidal Concentrations Induces Bacterial Membrane Depolarization in Staphylococcus aureus
  51. Glycopeptide antibiotics: Back to the future
  52. An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants
  53. Diverted total synthesis of falcitidin acyl tetrapeptides as new antimalarial leads
  54. Cardenolide Glycosides from Elaeodendron australe var. integrifolium
  55. Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
  56. Natural product and natural product derived drugs in clinical trials
  57. Natural Product Libraries: Assembly, Maintenance, and Screening.
  58. Remediating Cancer via Splicing Modulation
  59. Antibiotics in the clinical pipeline in 2013
  60. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae
  61. Isolation and synthesis of falcitidin, a novel myxobacterial-derived acyltetrapeptide with activity against the malaria target falcipain-2
  62. Resolving Biofilm Infections: Current Therapy and Drug Discovery Strategies
  63. Synthesis of 2-C-methylerythritols and 2-C-methylthreitols via enantiodivergent Sharpless dihydroxylation of trisubstituted olefins
  64. Structure aided design of chimeric antibiotics
  65. Absolute Configuration and Total Synthesis of a Novel Antimalarial Lipopeptide by the de Novo Preparation of Chiral Nonproteinogenic Amino Acids
  66. Identification of aluminium dioxalate in fungal cultures grown on vermiculite
  67. Screening Strategies to Identify New Antibiotics
  68. Identification of a Naturally Occurring Quinazolin-4(3H)-one Firefly Luciferase Inhibitor
  69. Antibiotics in the clinical pipeline in 2011
  70. Synthesis of Essramycin and Comparison of Its Antibacterial Activity
  71. A fast and straightforward route towards the synthesis of the lissoclimide class of anti-tumour agents
  72. ChemInform Abstract: Psammopemmins (A-C), Novel Brominated 4-Hydroxyindole Alkaloids from an Antarctic Sponge, Psammopemma sp.
  73. A Snapshot of Natural Product-Derived Compounds in Late Stage Clinical Development at the End of 2008
  74. A benzopyrroloisoquinoline alkaloid from Ficus fistulosa
  75. Microsphaerins A–D, four novel benzophenone dimers with activity against MRSA from the fungus Microsphaeropsis sp.
  76. Natural products to drugs: natural product-derived compounds in clinical trials
  77. A Simple Method for High-Throughput Extract Prefractionation for Biological Screening
  78. Natural products — The future scaffolds for novel antibiotics?
  79. Sundaicumones A and B, Polyprenylated Acylphloroglucinol Derivatives from Calophyllum sundaicum with Weak Activity against the Glucocorticoid Receptor
  80. Pyrrole Carboxamidine Tryptase Inhibitors from Leptonychia pubescens
  81. New Estrogenic Prenylflavone from Epimedium brevicornum Inhibits the Growth of Breast Cancer Cells
  82. Natural products to drugs: natural product derived compounds in clinical trials
  83. NMR spectral assignments of three aspidofractinine alkaloids, kopsine, fruticosine and fruticosamine
  84. Isolation and total synthesis of gymnastatin N, a POLO-like kinase 1 active constituent from the fungus Arachniotus punctatus
  85. The Role of Natural Product Chemistry in Drug Discovery
  86. Inhibition of the Human Chemokine Receptor CCR5 by Variecolin and Variecolol and Isolation of Four New Variecolin Analogues, Emericolins A−D, from Emericella aurantiobrunnea
  87. A new model for utilising chemical diversity from natural sources
  88. Cochlioquinones and Epi-Cochlioquinones: Antagonists of the Human Chemokine Receptor CCR5 from Bipolaris brizae and Stachybotrys chartarum.
  89. Phenolic derivatives from Wigandia urens with weak activity against the chemokine receptor CCR5
  90. 10-Methoxydihydrofuscin, Fuscinarin, and Fuscin, Novel Antagonists of the Human CCR5 Receptor from Oidiodendron griseum
  91. Ancisheynine, a novel naphthylisoquinolinium alkaloid from Ancistrocladus heyneanus
  92. Identification of Chelerythrine as an Inhibitor of BclXL Function
  93. Flavonoids from Artocarpus Lanceifolius
  94. Naturally Occurring Cembranes from an Australian Sarcophyton Species
  95. Three New Pyridoacridine Type Alkaloids from a Singaporean Ascidian
  96. Agonodepsides A and B:  Two New Depsides from a Filamentous Fungus F7524
  97. Spermine alkaloids from Albizia adinocephala with activity against Plasmodium falciparum plasmepsin II
  98. Ardisiaquinones from Ardisia teysmanniana
  99. Actephilol A and epiactephilol A: two novel aromatic terpenoids isolated from Actephila excelsa
  100. Circumdatin G, a New Alkaloid from the Fungus Aspergillus ochraceus
  101. 10-Hydroxydarlingine, a New Tropane Alkaloid from the Australian Proteaceous Plant Triunia erythrocarpa
  102. Anthoptilides A−E, New Briarane Diterpenes from the Australian Sea Pen Anthoptilum cf. kukenthali
  103. Isolation of Psammaplin A 11‘-Sulfate and Bisaprasin 11‘-Sulfate from the Marine Sponge Aplysinella rhax
  104. Tropane alkaloids from Darlingia darlingiana
  105. Isolation of Xestosterol Esters of Brominated Acetylenic Fatty Acids from the Marine Sponge Xestospongia testudinaria
  106. Adociasulfates 1−6, Inhibitors of Kinesin Motor Proteins from the Sponge Haliclona (aka Adocia ) sp.
  107. Adociasulfates 1, 7, and 8:  New Bioactive Hexaprenoid Hydroquinones from the Marine SpongeAdociasp.
  108. Two New Naphthoquinones from the Roots of Conospermum sphacelatum
  109. Dragmacidins:  New Protein Phosphatase Inhibitors from a Southern Australian Deep-Water Marine Sponge, Spongosorites sp.
  110. Isolation and Structure of Hemibastadinols 1−3 from the Papua New Guinea Marine Sponge Ianthella basta
  111. Antineoplastic Agents, 326. The Stereochemistry of Bastadins 8, 10, and 12 from the Bismarck Archipelago Marine Sponge lanthella basta
  112. Organic geochemical and geochemical studies of Inner Great Barrier Reef sediments—IV. Identification of terrigenous and marine sourced inputs
  113. Lamellarins O and P: New Aromatic Metabolites From the Australian Marine Sponge Dendrilla cactos
  114. Extraordinary levels of cadmium and zinc in a marine sponge,Tedania charcoti Topsent: inorganic chemical defense agents
  115. Trunculin-F and Contrunculin-A and -B: Novel Oxygenated Norterpenes From a Southern Australian Marine Sponge, Latrunculia conulosa
  116. Beyond Polygodial: New Drimane Sesquiterpenes From a Southern Australian Marine Sponge, Dysidea sp.
  117. Conulosins (A and B): Novel Norsesterterpene Acids from an Australian Marine Sponge, Latrunculia Conulosa
  118. The Luffarins (A-Z), Novel Terpenes From an Australian Marine Sponge, Luffariella geometrica
  119. Aromatic Disabolenes from an Australian Marine Sponge, Arenochalina sp.
  120. The Bastadins Revisited: New Chemistry From the Australian Marine Sponge Ianthella basta
  121. Norterpene Dienes From an Australian Marine Sponge Latrunculia brevis
  122. Mother Nature’s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery